Financial Performance - Net profit attributable to shareholders of the listed company was ¥6,600,292.89, a decrease of 40.37% year-on-year[9]. - Operating revenue for the period was ¥1,665,310,189.50, reflecting a growth of 2.23% compared to the same period last year[9]. - The company reported a net profit excluding non-recurring gains and losses of ¥6,488,268.52, a significant increase of 126.57% compared to the same period last year[9]. - Net profit for the period was CNY 22,107,600.75, down from CNY 30,531,695.98, indicating a decline of approximately 27.5%[28]. - The net profit attributable to the parent company was CNY 6,600,292.89, compared to CNY 11,069,101.42 in the previous period, a decrease of about 40.3%[28]. - Total comprehensive income for the current period is -¥41,143,842.03, up from -¥25,801,516.97 in the previous period, reflecting worsening financial performance[30]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥9,401,263,284.47, an increase of 0.35% compared to the end of the previous year[9]. - The company’s total net assets attributable to shareholders decreased by 0.33% to ¥944,734,698.66 compared to the end of the previous year[9]. - The company reported a decrease in current liabilities due to the expiration and refinancing of non-current liabilities, with a reduction of 40.84% from CNY 270,562,123.92 to CNY 160,072,936.37[14]. - Total assets increased to CNY 2,691,933,672.12 from CNY 2,401,341,634.90, reflecting a growth of approximately 12.1%[25]. - Total liabilities rose to CNY 1,770,773,309.90 from CNY 1,439,037,430.65, an increase of about 23.0%[25]. - The company's total equity decreased to CNY 921,160,362.22 from CNY 962,304,204.25, a decline of approximately 4.3%[25]. Cash Flow - The net cash flow from operating activities was ¥21,179,798.86, an increase of 6.75% year-on-year[9]. - Cash flow from operating activities shows a net inflow of ¥21,179,798.86, an increase from ¥19,839,681.75 in the previous period[34]. - Cash inflow from operating activities totaled ¥2,422,205,547.30, compared to ¥2,336,726,500.06 in the previous period, showing a positive trend[32]. - Cash outflow from investing activities resulted in a net outflow of -¥27,921,701.37, an improvement from -¥51,287,181.99 in the previous period[34]. - Cash inflow from financing activities was ¥1,109,001,404.16, slightly down from ¥1,184,941,344.60 in the previous period[34]. Shareholder Information - The total number of shareholders at the end of the reporting period was 42,628[12]. - The largest shareholder, Taiji Group Co., Ltd., held 38.81% of the shares, totaling 165,690,203 shares[12]. Expenses - Research and development expenses increased significantly by 1,383.08%, from CNY 22,692.97 to CNY 336,555.36, primarily due to the subsidiary's increased R&D activities[14]. - The company reported a significant increase in management expenses, rising to ¥13,036,783.54 from ¥4,605,648.96 in the previous period[30]. - Financial expenses increased to ¥20,170,171.09 from ¥15,565,969.90, indicating higher borrowing costs[30]. Inventory and Cash Management - The company’s cash and cash equivalents decreased slightly from CNY 1,803,361,973.43 to CNY 1,773,229,864.52, indicating a reduction in liquidity[19]. - The company’s inventory increased from CNY 1,456,677,780.34 to CNY 1,579,782,529.36, reflecting a growth of approximately 8.5%[19]. - The company’s cash and cash equivalents decreased to CNY 281,678,182.97 from CNY 319,393,019.58, a reduction of about 11.8%[23]. Other Financial Metrics - The weighted average return on net assets decreased by 0.53 percentage points to 0.70%[9]. - Basic earnings per share were ¥0.0155, down 40.15% from the previous year[9]. - Basic earnings per share for the period were CNY 0.0155, down from CNY 0.0259, representing a decrease of about 40.9%[28]. - The company reported a comprehensive income total of CNY 13,600,616.77, down from CNY 24,001,558.35, a decline of approximately 43.5%[28].

Financial Performance - The company's total revenue for 2013 was approximately CNY 6.60 billion, a slight increase of 0.01% compared to CNY 6.60 billion in 2012[18]. - The net profit attributable to shareholders for 2013 was CNY 12.56 million, a significant turnaround from a net loss of CNY 220.45 million in 2012, representing a 105.70% increase[18]. - The net profit after deducting non-recurring gains and losses was a loss of CNY 171.75 million, an improvement of 29.39% from a loss of CNY 243.22 million in 2012[18]. - The total profit for the year was 63.707 million RMB, an increase of 208.08 million RMB compared to a loss of 144.378 million RMB in the previous year[26]. - The net profit attributable to the parent company was 12.5598 million RMB, a significant increase of 233.0098 million RMB from a loss of 220.45 million RMB in the previous year[26]. - The company reported a net profit of 12,559,822.05 yuan for the year 2013, but did not propose a cash dividend distribution due to insufficient conditions[64]. - The company reported a significant increase in user data, reflecting a growing customer base and market penetration[92]. - The company achieved a net profit of CNY 300 million in 2013, which is an increase of 15% compared to the previous year[96]. Cash Flow and Operating Activities - The net cash flow from operating activities for 2013 was a negative CNY 139.45 million, a decline of 271.63% compared to a positive cash flow of CNY 81.25 million in 2012[18]. - The net cash flow from operating activities was negative at CNY -139.45 million, a significant decline of 271.63% compared to the previous year[31]. - The net cash flow from operating activities for the year was 176,189,303.29 RMB, a recovery from a negative cash flow of -329,276,583.99 RMB in the previous year, indicating a turnaround in operational performance[150]. - The total cash inflow from operating activities decreased to 7,513,504,339.76 RMB, down from 7,666,190,884.57 RMB, reflecting a year-over-year decline of approximately 2.0%[145]. - Cash outflow from operating activities increased to 7,652,953,653.62 RMB, compared to 7,584,938,555.38 RMB in the previous period, resulting in a rise of about 0.9%[145]. Assets and Liabilities - The total assets at the end of 2013 were approximately CNY 9.37 billion, an increase of 12.39% from CNY 8.34 billion in 2012[18]. - The total liabilities reached CNY 7,869,107,722.18, up from CNY 6,843,055,804.94 at the start of the year, indicating a significant increase in financial obligations[134]. - The total equity attributable to shareholders increased to CNY 947,886,746.11 from CNY 901,377,354.59, showing a growth of about 5.2%[134]. - The company's total assets as of December 31, 2013, amounted to CNY 9,368,082,454.63, an increase from CNY 8,335,299,156.74 at the beginning of the year[135]. Revenue Sources and Sales - The company achieved a sales revenue of 6.603 billion RMB, nearly unchanged from 6.602 billion RMB in the previous year[26]. - The company’s industrial sales reached 2.318 billion RMB, representing a growth of 4.74% compared to 2.213 billion RMB in the previous year[26]. - Commercial sales amounted to 4.154 billion RMB, a decrease of 2.63% from 4.266 billion RMB in the previous year[28]. - The company signed strategic cooperation agreements with top 100 chain pharmacies, achieving sales of 25.78 million RMB for the new product Tianjiao across 9,000 pharmacies[27]. Research and Development - Research and development expenses increased by 16.74% to CNY 21.11 million, representing 0.32% of total operating revenue[35][37]. - The company plans to develop 6-8 new products in the fields of anti-tumor drugs, pediatric medications, and health products, aiming for production licensing and standard filing for new products[61]. - The company is committed to developing high-value new products based on traditional Chinese medicine and enhancing its research and development capabilities[57]. Strategic Initiatives and Future Plans - The company aims to integrate resources from its three listed companies to create a "CNY 100 billion Taiji" enterprise[45]. - The company plans to enhance its production capacity and has made significant progress in GMP certification across multiple facilities[29]. - The company plans to actively pursue mergers and acquisitions in the pharmaceutical commercial sector to expand its market share[56]. - The company is focusing on technological advancements and research in traditional Chinese medicine to drive future growth[94]. Corporate Governance and Compliance - The company has established a long-term mechanism to prevent the controlling shareholder from occupying company funds[111]. - The company strictly adheres to information disclosure regulations, ensuring timely and equal access to information for all shareholders[113]. - The audit committee actively supervised the annual financial report and internal control audits, ensuring transparency and accuracy[118]. - The company has not reported any significant accounting errors or omissions during the reporting period[124]. Shareholder Information - The total number of shareholders at the end of the reporting period was 42,679, with 42,651 shareholders on the last trading day[85]. - The largest shareholder, Taiji Group Co., Ltd., holds 38.81% of shares, totaling 165,690,203 shares, with 79,970,000 shares pledged[85]. - The company has maintained a consistent share count of 426,894,000 shares, with no changes in restricted shares[84].